<!DOCTYPE html>
<html lang="en">
<head>
    <meta charset="UTF-8">
    <meta name="viewport" content="width=device-width, initial-scale=1.0">
    <title>Extraction extraction-result-234 - Theorizer</title>
    <link rel="stylesheet" href="https://cdnjs.cloudflare.com/ajax/libs/font-awesome/5.15.1/css/all.min.css">
    <link rel="stylesheet" href="../style.css">
</head>
<body>
    <div class="header">
        <a href="../index.html"><i class="fas fa-flask"></i> Theorizer</a>
    </div>

    <div class="content">
        <h1>Extracted Data Details for extraction-result-234</h1>

        <div class="section">
            <h2>Extracted Data (Header)</h2>
            <div class="info-section">
                <p><strong>Extraction ID:</strong> extraction-result-234</p>
                <p><strong>Extraction Schema Used (ID):</strong> <a href="../schemas/extraction-schema-9.html">extraction-schema-9</a></p>
                <div class="extraction-query"><strong>Extraction Query:</strong> Extract any mentions of mechanisms, models, explanations, and supporting or refuting evidence for why specific cancers preferentially metastasize to particular organs (metastatic organotropism), including details for cancer type, primary and metastatic sites, molecular or microenvironmental factors, and any quantitative or experimental evidence.</div>
                <p><strong>Paper ID:</strong> paper-0ea4b140bbc8fabc484ee21c11f398aba1f9b9b3</p>
                <p><strong>Paper Title:</strong> <a href="https://www.semanticscholar.org/paper/0ea4b140bbc8fabc484ee21c11f398aba1f9b9b3" target="_blank">Metastatic colonization by circulating tumour cells</a></p>
                <p><strong>Paper Venue:</strong> Nature</p>
                <p><strong>Paper TL;DR:</strong> An improved understanding of the mechanistic determinants of such colonization is needed to better prevent and treat metastatic cancer.</p>
                <p><strong>Cost:</strong> 0.018</p>
            </div>
        </div>

        <div class="section">
            <h2>Extracted Data (Details)</h2>
            <div class="extraction-instance-container" id="e234.0">
                <h3 class="extraction-instance">Extracted Data Instance 0 (e234.0)</h3>
                <div class="extraction-query"><strong>Extraction Query:</strong> Extract any mentions of mechanisms, models, explanations, and supporting or refuting evidence for why specific cancers preferentially metastasize to particular organs (metastatic organotropism), including details for cancer type, primary and metastatic sites, molecular or microenvironmental factors, and any quantitative or experimental evidence.</div>
                <table>
                    <thead>
                        <tr>
                            <th style="width: 30%;">Field</th>
                            <th style="width: 70%;">Value</th>
                        </tr>
                    </thead>
                    <tbody>
                        <tr>
                            <td><strong>name_short</strong></td>
                            <td>Breast->Lung organotropism</td>
                        </tr>
                        <tr>
                            <td><strong>name_full</strong></td>
                            <td>Breast cancer metastasis to lung</td>
                        </tr>
                        <tr>
                            <td><strong>brief_description</strong></td>
                            <td>Mechanisms by which breast carcinoma cells preferentially seed and grow in the lung, involving tumour-intrinsic genes for extravasation, pre-metastatic niche formation, and lung-specific stromal interactions that activate survival and stem-cell pathways.</td>
                        </tr>
                        <tr>
                            <td><strong>citation_title</strong></td>
                            <td>here</td>
                        </tr>
                        <tr>
                            <td><strong>mention_or_use</strong></td>
                            <td>mention</td>
                        </tr>
                        <tr>
                            <td><strong>cancer_type</strong></td>
                            <td>Breast carcinoma</td>
                        </tr>
                        <tr>
                            <td><strong>primary_site</strong></td>
                            <td>Breast</td>
                        </tr>
                        <tr>
                            <td><strong>preferred_metastatic_organ</strong></td>
                            <td>Lung</td>
                        </tr>
                        <tr>
                            <td><strong>proposed_mechanism</strong></td>
                            <td>Combination of anatomical trapping in pulmonary capillaries, tumour-derived priming of lung microenvironment (pre-metastatic niche), and cancer cell-autonomous expression of genes that increase extravasation and survival (e.g., ANGPTL4, COX2, MMP1, epiregulin, WNT ligands, Fascin-1), plus recruitment of supportive stromal/immune cells to amplify PI3K/AKT, MAPK and stem-cell pathways.</td>
                        </tr>
                        <tr>
                            <td><strong>supporting_evidence</strong></td>
                            <td>Experimental mouse models and xenografts showing that TGF-β induces ANGPTL4 in breast cancer cells to prime lung seeding; gene-expression screens identifying breast cancer genes that mediate lung metastasis (Minn et al.); models where tumour-derived systemic signals recruit bone-marrow-derived cells to lungs and increase extravasation and survival; association of these genes/signatures with lung relapse in clinical samples cited in the review.</td>
                        </tr>
                        <tr>
                            <td><strong>counter_evidence_or_alternative_explanations</strong></td>
                            <td>Anatomical circulation patterns (first-pass trapping) contribute but do not fully explain organotropism; many mediators provide only finite increases and act in parallel; EMT, previously implicated in dissemination, has been reported dispensable for metastasis in some breast models, indicating alternative mechanisms can compensate.</td>
                        </tr>
                        <tr>
                            <td><strong>key_molecules_or_factors</strong></td>
                            <td>ANGPTL4, COX2, MMP1, epiregulin, WNT ligands, Fascin-1, platelets (TGF-β, adenine nucleotides), macrophage contacts, exosomal integrins (targeting pre-metastatic niches), bone-marrow-derived VEGFR1+ cells</td>
                        </tr>
                        <tr>
                            <td><strong>experimental_model</strong></td>
                            <td>Mouse metastasis models (intravenous/arterial injection), orthotopic xenografts, gene-expression screens, clinical correlative data</td>
                        </tr>
                        <tr>
                            <td><strong>quantitative_data</strong></td>
                            <td>Review cites experimental findings that mediators produce 'finite' increases in seeding probability; specific numeric values not reported here for lung in this review (general note: many injected cells die within 2 days in lungs in mouse models).</td>
                        </tr>
                        <tr>
                            <td><strong>limitations_or_open_questions</strong></td>
                            <td>How long pre-metastatic niches persist in patients after primary tumour removal; which lung-specific stromal elements are essential at different colonization stages; temporal requirement of these mediators (infiltration vs latency vs outgrowth).</td>
                        </tr>
                        <tr>
                            <td><strong>source_info</strong></td>
                            <td>{'paper_title': 'Metastatic colonization by circulating tumour cells', 'publication_date_yy_mm': '2016-01'}</td>
                        </tr>
                    </tbody>
                </table>
            </div>
            <div class="extraction-instance-container" id="e234.1">
                <h3 class="extraction-instance">Extracted Data Instance 1 (e234.1)</h3>
                <div class="extraction-query"><strong>Extraction Query:</strong> Extract any mentions of mechanisms, models, explanations, and supporting or refuting evidence for why specific cancers preferentially metastasize to particular organs (metastatic organotropism), including details for cancer type, primary and metastatic sites, molecular or microenvironmental factors, and any quantitative or experimental evidence.</div>
                <table>
                    <thead>
                        <tr>
                            <th style="width: 30%;">Field</th>
                            <th style="width: 70%;">Value</th>
                        </tr>
                    </thead>
                    <tbody>
                        <tr>
                            <td><strong>name_short</strong></td>
                            <td>Breast->Brain organotropism</td>
                        </tr>
                        <tr>
                            <td><strong>name_full</strong></td>
                            <td>Breast cancer metastasis to brain</td>
                        </tr>
                        <tr>
                            <td><strong>brief_description</strong></td>
                            <td>Mechanisms enabling breast cancer cells to cross the blood–brain barrier, survive brain parenchymal defenses and exploit perivascular niches to grow in the brain.</td>
                        </tr>
                        <tr>
                            <td><strong>citation_title</strong></td>
                            <td>here</td>
                        </tr>
                        <tr>
                            <td><strong>mention_or_use</strong></td>
                            <td>mention</td>
                        </tr>
                        <tr>
                            <td><strong>cancer_type</strong></td>
                            <td>Breast carcinoma</td>
                        </tr>
                        <tr>
                            <td><strong>primary_site</strong></td>
                            <td>Breast</td>
                        </tr>
                        <tr>
                            <td><strong>preferred_metastatic_organ</strong></td>
                            <td>Brain</td>
                        </tr>
                        <tr>
                            <td><strong>proposed_mechanism</strong></td>
                            <td>Cancer-cell expression of specific extravasation mediators (ST6GalNac5, cathepsin S, microRNAs miR-105 and miR-181c) that disrupt endothelial/BBB integrity and promote transmigration; production of serine protease inhibitors (neuroserpin, serpin B2) to block astrocyte-derived plasmin-mediated apoptosis; perivascular co-option mediated by L1CAM and exploitation of capillary basal lamina to access perivascular niche and stem-cell signals.</td>
                        </tr>
                        <tr>
                            <td><strong>supporting_evidence</strong></td>
                            <td>Mouse and xenograft models showing that expression of ST6GalNac5, cathepsin S and specific microRNAs enhances brain extravasation; experiments demonstrating astrocyte plasminogen activator (PA) generates plasmin and FasL-mediated killing of DTCs, and that metastatic cells produce PA inhibitors (neuroserpin/serpin B2) to evade this defence; intravital imaging studies showing perivascular residence and L1CAM-mediated vascular co-option.</td>
                        </tr>
                        <tr>
                            <td><strong>counter_evidence_or_alternative_explanations</strong></td>
                            <td>Brain endothelial barrier complexity means only subsets of cells with specific traits succeed; the review notes many mediators act in parallel and individually give limited advantage; clinical kinetics vary by tumour type (e.g., brain relapse is late in breast cancer) suggesting additional factors influence timing.</td>
                        </tr>
                        <tr>
                            <td><strong>key_molecules_or_factors</strong></td>
                            <td>ST6GalNac5, cathepsin S, miR-105, miR-181c, neuroserpin, serpin B2, L1CAM, astrocyte-derived PA/plasmin/FasL</td>
                        </tr>
                        <tr>
                            <td><strong>experimental_model</strong></td>
                            <td>Mouse xenograft and intravital imaging models; in vitro BBB disruption assays; clinical correlation to brain metastasis incidence</td>
                        </tr>
                        <tr>
                            <td><strong>quantitative_data</strong></td>
                            <td>Review notes that many cancer cells that infiltrate the brain die (no specific percentages given here); brain metastasis incidence overall is ~10x higher than primary brain tumours combined (statement made without precise numeric value in this review).</td>
                        </tr>
                        <tr>
                            <td><strong>limitations_or_open_questions</strong></td>
                            <td>Which of the identified mediators are necessary vs sufficient in patients; mechanisms underlying late timing of brain relapse in some breast cancer subsets; therapeutic penetration of blood–brain barrier and targeting of perivascular niches.</td>
                        </tr>
                        <tr>
                            <td><strong>source_info</strong></td>
                            <td>{'paper_title': 'Metastatic colonization by circulating tumour cells', 'publication_date_yy_mm': '2016-01'}</td>
                        </tr>
                    </tbody>
                </table>
            </div>
            <div class="extraction-instance-container" id="e234.2">
                <h3 class="extraction-instance">Extracted Data Instance 2 (e234.2)</h3>
                <div class="extraction-query"><strong>Extraction Query:</strong> Extract any mentions of mechanisms, models, explanations, and supporting or refuting evidence for why specific cancers preferentially metastasize to particular organs (metastatic organotropism), including details for cancer type, primary and metastatic sites, molecular or microenvironmental factors, and any quantitative or experimental evidence.</div>
                <table>
                    <thead>
                        <tr>
                            <th style="width: 30%;">Field</th>
                            <th style="width: 70%;">Value</th>
                        </tr>
                    </thead>
                    <tbody>
                        <tr>
                            <td><strong>name_short</strong></td>
                            <td>Breast->Bone osteolytic</td>
                        </tr>
                        <tr>
                            <td><strong>name_full</strong></td>
                            <td>Breast cancer osteolytic bone metastasis</td>
                        </tr>
                        <tr>
                            <td><strong>brief_description</strong></td>
                            <td>A well-characterized vicious-cycle mechanism whereby breast cancer cells stimulate osteoclast-mediated bone resorption, releasing growth factors from bone that further drive tumour growth.</td>
                        </tr>
                        <tr>
                            <td><strong>citation_title</strong></td>
                            <td>here</td>
                        </tr>
                        <tr>
                            <td><strong>mention_or_use</strong></td>
                            <td>mention</td>
                        </tr>
                        <tr>
                            <td><strong>cancer_type</strong></td>
                            <td>Breast carcinoma</td>
                        </tr>
                        <tr>
                            <td><strong>primary_site</strong></td>
                            <td>Breast</td>
                        </tr>
                        <tr>
                            <td><strong>preferred_metastatic_organ</strong></td>
                            <td>Bone (osteolytic metastasis)</td>
                        </tr>
                        <tr>
                            <td><strong>proposed_mechanism</strong></td>
                            <td>Tumour cells produce factors (PTHrP, IL-11, TNF-α) that induce osteoblasts to up-regulate RANKL, promoting osteoclast maturation and bone resorption; matrix degradation (MMPs) and reduced osteoprotegerin amplify RANKL effects; bone matrix degradation releases TGF-β, which stimulates tumour production of PTHrP and IL-11, creating a feed-forward 'vicious cycle'. Additional tumour ligands (Jagged1, VCAM-1, sICAM-1) mobilize osteoclasts.</td>
                        </tr>
                        <tr>
                            <td><strong>supporting_evidence</strong></td>
                            <td>Experimental studies and models cited implicate PTHrP, IL-11, TNF-α, MMPs, Jagged1 and adhesion molecules in osteoclast activation and osteolysis; blockade of TGF-β reduces PTHrP and bone metastasis in models; clinical relevance supported by therapeutic success of osteoclast-targeting agents (bisphosphonates, denosumab) in reducing skeletal morbidity and in adjuvant settings.</td>
                        </tr>
                        <tr>
                            <td><strong>counter_evidence_or_alternative_explanations</strong></td>
                            <td>Prostate cancer shows osteoblastic rather than osteolytic bone metastasis via different factors, indicating bone colonization outcomes depend on cancer-specific programs; review acknowledges incomplete knowledge of organ-specific traits beyond bone.</td>
                        </tr>
                        <tr>
                            <td><strong>key_molecules_or_factors</strong></td>
                            <td>PTHrP, IL-11, TNF-α, RANKL, osteoprotegerin (OPG), MMPs (e.g., MMP-7), Jagged1, VCAM-1, sICAM-1, TGF-β</td>
                        </tr>
                        <tr>
                            <td><strong>experimental_model</strong></td>
                            <td>Mouse bone metastasis models, cell-based assays, molecular perturbation (TGF-β blockade), clinical trials/meta-analyses of osteoclast inhibitors</td>
                        </tr>
                        <tr>
                            <td><strong>quantitative_data</strong></td>
                            <td>Review references meta-analysis showing adjuvant bisphosphonates suppress bone metastasis and prolong survival in postmenopausal women (no numeric effect size given in this review); denosumab reduces incidence of bone fractures in treated patients (no percent provided here).</td>
                        </tr>
                        <tr>
                            <td><strong>limitations_or_open_questions</strong></td>
                            <td>Relative contribution of individual mediators in patients; timing and context in which bone-specific programs are induced; mechanisms distinguishing osteolytic vs osteoblastic programs.</td>
                        </tr>
                        <tr>
                            <td><strong>source_info</strong></td>
                            <td>{'paper_title': 'Metastatic colonization by circulating tumour cells', 'publication_date_yy_mm': '2016-01'}</td>
                        </tr>
                    </tbody>
                </table>
            </div>
            <div class="extraction-instance-container" id="e234.3">
                <h3 class="extraction-instance">Extracted Data Instance 3 (e234.3)</h3>
                <div class="extraction-query"><strong>Extraction Query:</strong> Extract any mentions of mechanisms, models, explanations, and supporting or refuting evidence for why specific cancers preferentially metastasize to particular organs (metastatic organotropism), including details for cancer type, primary and metastatic sites, molecular or microenvironmental factors, and any quantitative or experimental evidence.</div>
                <table>
                    <thead>
                        <tr>
                            <th style="width: 30%;">Field</th>
                            <th style="width: 70%;">Value</th>
                        </tr>
                    </thead>
                    <tbody>
                        <tr>
                            <td><strong>name_short</strong></td>
                            <td>Prostate->Bone osteoblastic</td>
                        </tr>
                        <tr>
                            <td><strong>name_full</strong></td>
                            <td>Prostate cancer osteoblastic bone metastasis</td>
                        </tr>
                        <tr>
                            <td><strong>brief_description</strong></td>
                            <td>Prostate cancer cells preferentially colonize bone by stimulating osteoblastic activity and new bone formation through secretion of growth and morphogenetic factors.</td>
                        </tr>
                        <tr>
                            <td><strong>citation_title</strong></td>
                            <td>here</td>
                        </tr>
                        <tr>
                            <td><strong>mention_or_use</strong></td>
                            <td>mention</td>
                        </tr>
                        <tr>
                            <td><strong>cancer_type</strong></td>
                            <td>Prostate carcinoma</td>
                        </tr>
                        <tr>
                            <td><strong>primary_site</strong></td>
                            <td>Prostate</td>
                        </tr>
                        <tr>
                            <td><strong>preferred_metastatic_organ</strong></td>
                            <td>Bone (osteoblastic metastasis)</td>
                        </tr>
                        <tr>
                            <td><strong>proposed_mechanism</strong></td>
                            <td>Cancer cells secrete factors (FGFs, IGFs, VEGF, endothelin 1, Wnt ligands, BMPs) that stimulate osteoblast differentiation and bone matrix deposition, leading to osteoblastic lesions and displacement of marrow.</td>
                        </tr>
                        <tr>
                            <td><strong>supporting_evidence</strong></td>
                            <td>Experimental observations linking these secreted factors to osteoblastic changes in bone metastasis models; cited literature describing prostate metastasis targeting the hematopoietic stem cell niche and co-opting bone microenvironment.</td>
                        </tr>
                        <tr>
                            <td><strong>counter_evidence_or_alternative_explanations</strong></td>
                            <td>Not all prostate bone metastases are uniformly osteoblastic; bone responses can be heterogeneous and mixed; mechanisms differ markedly from osteolytic programs in other cancers.</td>
                        </tr>
                        <tr>
                            <td><strong>key_molecules_or_factors</strong></td>
                            <td>FGFs, IGFs, VEGF, endothelin 1, Wnt factors, BMPs</td>
                        </tr>
                        <tr>
                            <td><strong>experimental_model</strong></td>
                            <td>Mouse bone metastasis models, patient observations, niche-targeting studies</td>
                        </tr>
                        <tr>
                            <td><strong>quantitative_data</strong></td>
                            <td>No specific quantitative rates given in this review for prostate-to-bone frequency; qualitative high propensity noted.</td>
                        </tr>
                        <tr>
                            <td><strong>limitations_or_open_questions</strong></td>
                            <td>Detailed causal pathways in patients; interplay between osteoblastic signalling and tumour cell survival; potential shared vs unique drivers across prostate patients.</td>
                        </tr>
                        <tr>
                            <td><strong>source_info</strong></td>
                            <td>{'paper_title': 'Metastatic colonization by circulating tumour cells', 'publication_date_yy_mm': '2016-01'}</td>
                        </tr>
                    </tbody>
                </table>
            </div>
            <div class="extraction-instance-container" id="e234.4">
                <h3 class="extraction-instance">Extracted Data Instance 4 (e234.4)</h3>
                <div class="extraction-query"><strong>Extraction Query:</strong> Extract any mentions of mechanisms, models, explanations, and supporting or refuting evidence for why specific cancers preferentially metastasize to particular organs (metastatic organotropism), including details for cancer type, primary and metastatic sites, molecular or microenvironmental factors, and any quantitative or experimental evidence.</div>
                <table>
                    <thead>
                        <tr>
                            <th style="width: 30%;">Field</th>
                            <th style="width: 70%;">Value</th>
                        </tr>
                    </thead>
                    <tbody>
                        <tr>
                            <td><strong>name_short</strong></td>
                            <td>Colorectal->Liver</td>
                        </tr>
                        <tr>
                            <td><strong>name_full</strong></td>
                            <td>Colorectal cancer metastasis to liver</td>
                        </tr>
                        <tr>
                            <td><strong>brief_description</strong></td>
                            <td>Colon and rectal cancers preferentially metastasize to the liver, aided by portal venous drainage, liver sinusoidal endothelium permissive of extravasation, and tumour–stroma signaling (e.g., TGF-β programs recruiting supportive stromal IL-11).</td>
                        </tr>
                        <tr>
                            <td><strong>citation_title</strong></td>
                            <td>here</td>
                        </tr>
                        <tr>
                            <td><strong>mention_or_use</strong></td>
                            <td>mention</td>
                        </tr>
                        <tr>
                            <td><strong>cancer_type</strong></td>
                            <td>Colorectal carcinoma</td>
                        </tr>
                        <tr>
                            <td><strong>primary_site</strong></td>
                            <td>Colon/rectum</td>
                        </tr>
                        <tr>
                            <td><strong>preferred_metastatic_organ</strong></td>
                            <td>Liver</td>
                        </tr>
                        <tr>
                            <td><strong>proposed_mechanism</strong></td>
                            <td>Anatomical route (mesenteric venous drainage to liver) causes first-pass exposure; liver sinusoidal capillaries (fenestrated, discontinuous basal lamina) facilitate extravasation; tumour cell-autonomous TGF-β signaling recruits stromal mesenchymal cells that supply IL-11 to activate Stat3 in cancer cells; other pre-metastatic niche factors (exosomes, cytokines) condition liver microenvironment.</td>
                        </tr>
                        <tr>
                            <td><strong>supporting_evidence</strong></td>
                            <td>Clinical capture of CTCs in liver of colorectal cancer patients; experimental models showing colorectal cancer stem cells in liver express TGF-β to recruit mesenchymal cells supplying IL-11 for Stat3 activation; pancreatic cancer exosome studies showing liver pre-metastatic niche formation (analogous mechanisms cited).</td>
                        </tr>
                        <tr>
                            <td><strong>counter_evidence_or_alternative_explanations</strong></td>
                            <td>Presence of DTCs in bone marrow for colorectal/gastric cancers but low bone metastasis incidence illustrates that seeding does not equal colonization; anatomical route explains initial arrest but not eventual outgrowth—requires additional supportive cues.</td>
                        </tr>
                        <tr>
                            <td><strong>key_molecules_or_factors</strong></td>
                            <td>TGF-β (tumour-derived), IL-11 (stromal), Stat3 pathway, sinusoidal endothelial fenestrations, exosomes, fibronectin</td>
                        </tr>
                        <tr>
                            <td><strong>experimental_model</strong></td>
                            <td>Mouse xenografts, organ capture studies in patients, molecular perturbation (TGF-β/IL-11/Stat3)</td>
                        </tr>
                        <tr>
                            <td><strong>quantitative_data</strong></td>
                            <td>Clinical note: many DTCs can be present in bone marrow without later bone metastasis; specific numeric liver metastasis rates for colorectal cancer not provided in review.</td>
                        </tr>
                        <tr>
                            <td><strong>limitations_or_open_questions</strong></td>
                            <td>Why many DTCs remain latent without forming overt liver metastases in some settings; longevity of pre-metastatic niche priming in patients after primary tumour removal.</td>
                        </tr>
                        <tr>
                            <td><strong>source_info</strong></td>
                            <td>{'paper_title': 'Metastatic colonization by circulating tumour cells', 'publication_date_yy_mm': '2016-01'}</td>
                        </tr>
                    </tbody>
                </table>
            </div>
            <div class="extraction-instance-container" id="e234.5">
                <h3 class="extraction-instance">Extracted Data Instance 5 (e234.5)</h3>
                <div class="extraction-query"><strong>Extraction Query:</strong> Extract any mentions of mechanisms, models, explanations, and supporting or refuting evidence for why specific cancers preferentially metastasize to particular organs (metastatic organotropism), including details for cancer type, primary and metastatic sites, molecular or microenvironmental factors, and any quantitative or experimental evidence.</div>
                <table>
                    <thead>
                        <tr>
                            <th style="width: 30%;">Field</th>
                            <th style="width: 70%;">Value</th>
                        </tr>
                    </thead>
                    <tbody>
                        <tr>
                            <td><strong>name_short</strong></td>
                            <td>Melanoma organotropism & oxidative stress</td>
                        </tr>
                        <tr>
                            <td><strong>name_full</strong></td>
                            <td>Melanoma metastasis organotropism and metabolic stress adaptations</td>
                        </tr>
                        <tr>
                            <td><strong>brief_description</strong></td>
                            <td>Melanoma metastasis depends on metabolic adaptations to oxidative stress during dissemination and exosome-mediated pre-metastatic niche formation influencing organ targeting.</td>
                        </tr>
                        <tr>
                            <td><strong>citation_title</strong></td>
                            <td>here</td>
                        </tr>
                        <tr>
                            <td><strong>mention_or_use</strong></td>
                            <td>mention</td>
                        </tr>
                        <tr>
                            <td><strong>cancer_type</strong></td>
                            <td>Melanoma</td>
                        </tr>
                        <tr>
                            <td><strong>primary_site</strong></td>
                            <td>Skin (melanoma)</td>
                        </tr>
                        <tr>
                            <td><strong>preferred_metastatic_organ</strong></td>
                            <td>Multiple organs (including lymph nodes, lung, liver); review highlights liver tropism for uveal melanoma specifically</td>
                        </tr>
                        <tr>
                            <td><strong>proposed_mechanism</strong></td>
                            <td>Requirement for resistance to oxidative stress during transit and colonization (dependence on folate pathway NADPH-generating enzymes); tumour exosomes educate bone-marrow progenitors and induce vascular leakiness/inflammation to form pre-metastatic niches; exosomal integrins may direct organ-specific delivery of cargo.</td>
                        </tr>
                        <tr>
                            <td><strong>supporting_evidence</strong></td>
                            <td>Mouse experiments showing melanoma cells depend on folate pathway NADPH enzymes and that inhibition reduces overt metastasis; antioxidant supplementation increased lymph node metastases in mice; melanoma exosome studies in models inducing vascular leakiness, inflammation, and recruitment of progenitor cells.</td>
                        </tr>
                        <tr>
                            <td><strong>counter_evidence_or_alternative_explanations</strong></td>
                            <td>Antioxidant effects varied by site (increased lymph node metastasis but not primary growth); organotropism likely multi-factorial—metabolic adaptations are one component among many parallel mechanisms.</td>
                        </tr>
                        <tr>
                            <td><strong>key_molecules_or_factors</strong></td>
                            <td>Folate pathway NADPH-generating enzymes, exosomes, MET (in exosome cargo per cited studies), integrins on exosomes, antioxidant small molecules</td>
                        </tr>
                        <tr>
                            <td><strong>experimental_model</strong></td>
                            <td>Mouse metastasis models, antioxidant supplementation experiments, exosome transfer studies</td>
                        </tr>
                        <tr>
                            <td><strong>quantitative_data</strong></td>
                            <td>Portal-vein injected melanoma: majority failed to form micrometastases in liver and only 0.02% formed macrometastases (specific number reported in review referencing older studies).</td>
                        </tr>
                        <tr>
                            <td><strong>limitations_or_open_questions</strong></td>
                            <td>Extent to which exosome-targeting integrins determine organotropism in patients; clinical relevance of antioxidant effects; interplay between metabolic adaptations and stromal cues at colonization.</td>
                        </tr>
                        <tr>
                            <td><strong>source_info</strong></td>
                            <td>{'paper_title': 'Metastatic colonization by circulating tumour cells', 'publication_date_yy_mm': '2016-01'}</td>
                        </tr>
                    </tbody>
                </table>
            </div>
            <div class="extraction-instance-container" id="e234.6">
                <h3 class="extraction-instance">Extracted Data Instance 6 (e234.6)</h3>
                <div class="extraction-query"><strong>Extraction Query:</strong> Extract any mentions of mechanisms, models, explanations, and supporting or refuting evidence for why specific cancers preferentially metastasize to particular organs (metastatic organotropism), including details for cancer type, primary and metastatic sites, molecular or microenvironmental factors, and any quantitative or experimental evidence.</div>
                <table>
                    <thead>
                        <tr>
                            <th style="width: 30%;">Field</th>
                            <th style="width: 70%;">Value</th>
                        </tr>
                    </thead>
                    <tbody>
                        <tr>
                            <td><strong>name_short</strong></td>
                            <td>Uveal->Liver</td>
                        </tr>
                        <tr>
                            <td><strong>name_full</strong></td>
                            <td>Uveal melanoma metastasis to liver</td>
                        </tr>
                        <tr>
                            <td><strong>brief_description</strong></td>
                            <td>Clinical observation that uveal melanoma displays strong liver tropism; mechanisms are discussed in the context of organ-specific colonization but are not deeply elaborated in this review.</td>
                        </tr>
                        <tr>
                            <td><strong>citation_title</strong></td>
                            <td>here</td>
                        </tr>
                        <tr>
                            <td><strong>mention_or_use</strong></td>
                            <td>mention</td>
                        </tr>
                        <tr>
                            <td><strong>cancer_type</strong></td>
                            <td>Uveal melanoma</td>
                        </tr>
                        <tr>
                            <td><strong>primary_site</strong></td>
                            <td>Uveal tract of the eye</td>
                        </tr>
                        <tr>
                            <td><strong>preferred_metastatic_organ</strong></td>
                            <td>Liver</td>
                        </tr>
                        <tr>
                            <td><strong>proposed_mechanism</strong></td>
                            <td>Not specified in detail in this review; cited as an example of strong organ-specific propensity, implying tumor- and organ-specific colonization traits but mechanisms remain to be defined.</td>
                        </tr>
                        <tr>
                            <td><strong>supporting_evidence</strong></td>
                            <td>Clinical epidemiology: marked propensity of uveal melanoma to relapse in liver (stated in review); underlying molecular mechanisms not detailed here.</td>
                        </tr>
                        <tr>
                            <td><strong>counter_evidence_or_alternative_explanations</strong></td>
                            <td>Review notes marked propensities across tumour types but acknowledges limited mechanistic knowledge beyond well-studied cases like bone metastasis.</td>
                        </tr>
                        <tr>
                            <td><strong>key_molecules_or_factors</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>experimental_model</strong></td>
                            <td>Clinical observation and epidemiologic data (no specific mechanistic models discussed in this review)</td>
                        </tr>
                        <tr>
                            <td><strong>quantitative_data</strong></td>
                            <td>No quantitative rates provided in this review (qualitative high propensity only).</td>
                        </tr>
                        <tr>
                            <td><strong>limitations_or_open_questions</strong></td>
                            <td>Mechanistic basis for uveal melanoma liver tropism is not described here and remains an open question for further study.</td>
                        </tr>
                        <tr>
                            <td><strong>source_info</strong></td>
                            <td>{'paper_title': 'Metastatic colonization by circulating tumour cells', 'publication_date_yy_mm': '2016-01'}</td>
                        </tr>
                    </tbody>
                </table>
            </div>
            <div class="extraction-instance-container" id="e234.7">
                <h3 class="extraction-instance">Extracted Data Instance 7 (e234.7)</h3>
                <div class="extraction-query"><strong>Extraction Query:</strong> Extract any mentions of mechanisms, models, explanations, and supporting or refuting evidence for why specific cancers preferentially metastasize to particular organs (metastatic organotropism), including details for cancer type, primary and metastatic sites, molecular or microenvironmental factors, and any quantitative or experimental evidence.</div>
                <table>
                    <thead>
                        <tr>
                            <th style="width: 30%;">Field</th>
                            <th style="width: 70%;">Value</th>
                        </tr>
                    </thead>
                    <tbody>
                        <tr>
                            <td><strong>name_short</strong></td>
                            <td>Lung adenocarcinoma->Brain</td>
                        </tr>
                        <tr>
                            <td><strong>name_full</strong></td>
                            <td>Lung adenocarcinoma metastasis to brain</td>
                        </tr>
                        <tr>
                            <td><strong>brief_description</strong></td>
                            <td>Lung adenocarcinomas frequently metastasize early to brain; mechanisms overlap with those of other carcinomas for brain colonization involving BBB traversal and astrocyte interactions.</td>
                        </tr>
                        <tr>
                            <td><strong>citation_title</strong></td>
                            <td>here</td>
                        </tr>
                        <tr>
                            <td><strong>mention_or_use</strong></td>
                            <td>mention</td>
                        </tr>
                        <tr>
                            <td><strong>cancer_type</strong></td>
                            <td>Lung adenocarcinoma</td>
                        </tr>
                        <tr>
                            <td><strong>primary_site</strong></td>
                            <td>Lung</td>
                        </tr>
                        <tr>
                            <td><strong>preferred_metastatic_organ</strong></td>
                            <td>Brain</td>
                        </tr>
                        <tr>
                            <td><strong>proposed_mechanism</strong></td>
                            <td>Arterial circulation delivers CTCs to brain; extravasation requires disruption of the BBB via proteases/microRNAs and other mediators similar to breast cancer brain metastasis; once in brain, tumour cells counter astrocyte-mediated plasmin/FasL killing by producing PA inhibitors and engage perivascular niches.</td>
                        </tr>
                        <tr>
                            <td><strong>supporting_evidence</strong></td>
                            <td>Reference to studies showing many CTCs lodge in brain and die; mediators ST6GalNac5, cathepsin S, miR-105/miR-181c implicated in brain extravasation (originally described in breast cancer models but discussed as relevant to brain metastasis of multiple tumour types), and astrocyte defence mechanisms described with tumour countermeasures.</td>
                        </tr>
                        <tr>
                            <td><strong>counter_evidence_or_alternative_explanations</strong></td>
                            <td>Brain relapse timing differs by tumour type (earlier in lung cancer than breast), suggesting tumour-intrinsic and clinical treatment context matter; specific lung-cancer-exclusive mediators are not deeply elaborated in this review.</td>
                        </tr>
                        <tr>
                            <td><strong>key_molecules_or_factors</strong></td>
                            <td>ST6GalNac5, cathepsin S, miR-105, miR-181c, neuroserpin/serpin B2 (PA inhibitors), astrocyte-derived PA/plasmin/FasL</td>
                        </tr>
                        <tr>
                            <td><strong>experimental_model</strong></td>
                            <td>Mouse models of brain metastasis, intravital imaging, molecular perturbation studies (largely performed in breast/lung model systems referenced)</td>
                        </tr>
                        <tr>
                            <td><strong>quantitative_data</strong></td>
                            <td>Statement that lung cancer frequently relapses in brain early (qualitative); many cancer cells that infiltrate brain die (no percentage given).</td>
                        </tr>
                        <tr>
                            <td><strong>limitations_or_open_questions</strong></td>
                            <td>Tumour-type specific mediators for early brain relapse; how therapy-induced systemic changes modify brain colonization risk.</td>
                        </tr>
                        <tr>
                            <td><strong>source_info</strong></td>
                            <td>{'paper_title': 'Metastatic colonization by circulating tumour cells', 'publication_date_yy_mm': '2016-01'}</td>
                        </tr>
                    </tbody>
                </table>
            </div>
            <div class="extraction-instance-container" id="e234.8">
                <h3 class="extraction-instance">Extracted Data Instance 8 (e234.8)</h3>
                <div class="extraction-query"><strong>Extraction Query:</strong> Extract any mentions of mechanisms, models, explanations, and supporting or refuting evidence for why specific cancers preferentially metastasize to particular organs (metastatic organotropism), including details for cancer type, primary and metastatic sites, molecular or microenvironmental factors, and any quantitative or experimental evidence.</div>
                <table>
                    <thead>
                        <tr>
                            <th style="width: 30%;">Field</th>
                            <th style="width: 70%;">Value</th>
                        </tr>
                    </thead>
                    <tbody>
                        <tr>
                            <td><strong>name_short</strong></td>
                            <td>RCC VHL-HIF epigenetic expansion</td>
                        </tr>
                        <tr>
                            <td><strong>name_full</strong></td>
                            <td>Renal cell carcinoma VHL-HIF epigenetic expansion driving multiorgan metastasis</td>
                        </tr>
                        <tr>
                            <td><strong>brief_description</strong></td>
                            <td>In VHL-mutant renal cell carcinoma, epigenetic changes (DNA methylation, histone acetylation) expand HIF transcriptional output, enabling metastatic activity across multiple organs.</td>
                        </tr>
                        <tr>
                            <td><strong>citation_title</strong></td>
                            <td>here</td>
                        </tr>
                        <tr>
                            <td><strong>mention_or_use</strong></td>
                            <td>mention</td>
                        </tr>
                        <tr>
                            <td><strong>cancer_type</strong></td>
                            <td>Renal cell carcinoma (VHL-mutant)</td>
                        </tr>
                        <tr>
                            <td><strong>primary_site</strong></td>
                            <td>Kidney</td>
                        </tr>
                        <tr>
                            <td><strong>preferred_metastatic_organ</strong></td>
                            <td>Multiple organs (multiorgan metastasis)</td>
                        </tr>
                        <tr>
                            <td><strong>proposed_mechanism</strong></td>
                            <td>Epigenetic alterations broaden the scope of HIF target gene expression, amplifying HIF pathway outputs and enabling traits favorable for colonization in multiple organ microenvironments.</td>
                        </tr>
                        <tr>
                            <td><strong>supporting_evidence</strong></td>
                            <td>Cited study showing DNA methylation and histone acetylation changes in VHL-mutant RCC expand HIF target gene range and are associated with increased metastatic activity to multiple organs (Vanharanta et al.).</td>
                        </tr>
                        <tr>
                            <td><strong>counter_evidence_or_alternative_explanations</strong></td>
                            <td>No recurrent metastasis-specific mutations identified broadly, suggesting epigenetic and non-genetic regulation often underlie organotropic traits; mechanism demonstrated in RCC may not generalize to other tumour types.</td>
                        </tr>
                        <tr>
                            <td><strong>key_molecules_or_factors</strong></td>
                            <td>VHL mutation, HIF pathway, HIF target genes, DNA methylation, histone acetylation</td>
                        </tr>
                        <tr>
                            <td><strong>experimental_model</strong></td>
                            <td>Molecular and epigenetic analyses in RCC models and clinical samples (as cited in review)</td>
                        </tr>
                        <tr>
                            <td><strong>quantitative_data</strong></td>
                            <td>Review does not provide numeric metastasis rates for RCC in this context; describes multiorgan metastatic activity qualitatively.</td>
                        </tr>
                        <tr>
                            <td><strong>limitations_or_open_questions</strong></td>
                            <td>How expanded HIF output maps to specific organ colonization traits; generalizability of epigenetic expansion mechanisms across cancers.</td>
                        </tr>
                        <tr>
                            <td><strong>source_info</strong></td>
                            <td>{'paper_title': 'Metastatic colonization by circulating tumour cells', 'publication_date_yy_mm': '2016-01'}</td>
                        </tr>
                    </tbody>
                </table>
            </div>
            <div class="extraction-instance-container" id="e234.9">
                <h3 class="extraction-instance">Extracted Data Instance 9 (e234.9)</h3>
                <div class="extraction-query"><strong>Extraction Query:</strong> Extract any mentions of mechanisms, models, explanations, and supporting or refuting evidence for why specific cancers preferentially metastasize to particular organs (metastatic organotropism), including details for cancer type, primary and metastatic sites, molecular or microenvironmental factors, and any quantitative or experimental evidence.</div>
                <table>
                    <thead>
                        <tr>
                            <th style="width: 30%;">Field</th>
                            <th style="width: 70%;">Value</th>
                        </tr>
                    </thead>
                    <tbody>
                        <tr>
                            <td><strong>name_short</strong></td>
                            <td>Pre-metastatic niche via exosomes/integrins</td>
                        </tr>
                        <tr>
                            <td><strong>name_full</strong></td>
                            <td>Tumour exosome-mediated pre-metastatic niche targeting (integrin-directed)</td>
                        </tr>
                        <tr>
                            <td><strong>brief_description</strong></td>
                            <td>Tumour-derived exosomes carry proteins and nucleic acids that prime specific distant organs for colonization; integrins on exosomes may direct them to particular organs and determine organotropic preconditioning.</td>
                        </tr>
                        <tr>
                            <td><strong>citation_title</strong></td>
                            <td>here</td>
                        </tr>
                        <tr>
                            <td><strong>mention_or_use</strong></td>
                            <td>mention</td>
                        </tr>
                        <tr>
                            <td><strong>cancer_type</strong></td>
                            <td>Multiple tumour types (breast, lung, pancreatic, melanoma cited)</td>
                        </tr>
                        <tr>
                            <td><strong>primary_site</strong></td>
                            <td>Various</td>
                        </tr>
                        <tr>
                            <td><strong>preferred_metastatic_organ</strong></td>
                            <td>Organ-specific depending on exosomal integrin composition (e.g., liver, lung, bone depending on integrins and cargo)</td>
                        </tr>
                        <tr>
                            <td><strong>proposed_mechanism</strong></td>
                            <td>Tumour exosomes travel systemically, adhere to target organ cells guided by exosomal integrins, unload cargo that induces vascular leakiness, inflammation, fibronectin production and recruitment of bone-marrow-derived cells, thereby creating a supportive pre-metastatic niche.</td>
                        </tr>
                        <tr>
                            <td><strong>supporting_evidence</strong></td>
                            <td>Mouse studies: melanoma exosomes induced vascular leakiness and bone-marrow progenitor recruitment; pancreatic cancer exosomes induced liver stellate cell activation and fibronectin deposition; cited in-press work suggests integrin patterns on exosomes determine organ targeting.</td>
                        </tr>
                        <tr>
                            <td><strong>counter_evidence_or_alternative_explanations</strong></td>
                            <td>Clinical relevance and longevity of pre-metastatic niches in human patients remain uncertain—whether niches remain primed for years after primary tumour removal is an open question.</td>
                        </tr>
                        <tr>
                            <td><strong>key_molecules_or_factors</strong></td>
                            <td>Exosomes, integrins on exosomes, MIF (in pancreatic exosomes), fibronectin, VEGFR1+ bone-marrow progenitors</td>
                        </tr>
                        <tr>
                            <td><strong>experimental_model</strong></td>
                            <td>Mouse models of exosome transfer, organ-tropic pre-metastatic niche assays, cellular analyses</td>
                        </tr>
                        <tr>
                            <td><strong>quantitative_data</strong></td>
                            <td>No precise numeric organotropism rates provided in the review for exosome targeting; qualitative experimental evidence cited.</td>
                        </tr>
                        <tr>
                            <td><strong>limitations_or_open_questions</strong></td>
                            <td>Persistence of pre-metastatic niches over clinical timescales; degree to which exosomal targeting explains patient organotropism vs other factors.</td>
                        </tr>
                        <tr>
                            <td><strong>source_info</strong></td>
                            <td>{'paper_title': 'Metastatic colonization by circulating tumour cells', 'publication_date_yy_mm': '2016-01'}</td>
                        </tr>
                    </tbody>
                </table>
            </div>
        </div>

        <div class="section">
            <h2>Potentially Relevant New Papers (mentioned by this paper)</h2>
            <ol>
                <li>Genes that mediate breast cancer metastasis to lung <em>(Rating: 2)</em></li>
                <li>Genes that mediate breast cancer metastasis to the brain <em>(Rating: 2)</em></li>
                <li>VEGFR1-positive haematopoietic bone marrow progenitors initiate the pre-metastatic niche <em>(Rating: 2)</em></li>
                <li>Pancreatic cancer exosomes initiate pre-metastatic niche formation in the liver <em>(Rating: 2)</em></li>
                <li>Melanoma exosomes educate bone marrow progenitor cells toward a pro-metastatic phenotype through MET <em>(Rating: 2)</em></li>
                <li>Breast cancer cells produce tenascin C as a metastatic niche component to colonize the lungs <em>(Rating: 2)</em></li>
                <li>Latent bone metastasis in breast cancer tied to Src-dependent survival signals <em>(Rating: 2)</em></li>
                <li>Epigenetic expansion of VHL-HIF signal output drives multiorgan metastasis in renal cancer <em>(Rating: 2)</em></li>
                <li>The hypoxic cancer secretome induces pre-metastatic bone lesions through lysyl oxidase <em>(Rating: 2)</em></li>
                <li>Tumour exosome integrins determine organotropic metastasis <em>(Rating: 2)</em></li>
            </ol>
        </div>

        </div>

    </div>
</body>
</html>